Indiana University Research & Technology Corporation

United States of America

Back to Profile

1-100 of 147 for Indiana University Research & Technology Corporation Sort by
Query
Aggregations
Jurisdiction
        World 100
        United States 32
        Canada 15
Date
2024 1
2023 1
2022 2
2021 1
Before 2020 142
IPC Class
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids 8
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells 7
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells 7
A61K 31/00 - Medicinal preparations containing organic active ingredients 6
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin 6
See more
Status
Pending 8
Registered / In Force 139
Found results for  patents
  1     2        Next Page

1.

SCALABLE ANION CAPTURE MACROCYCLES

      
Application Number 18104469
Status Pending
Filing Date 2021-10-13
First Publication Date 2024-08-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Flood, Amar Hugh
  • Dobscha, James Robert

Abstract

The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I): The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I): The present disclosure concerns scalable single-pot synthesis, anion binding features, liquid-liquid extraction of salts of the triazolophane macrocycle of Formula (I): wherein the substituents R are independently selected from the group consisting of a linear and branched alkyl, a linear and branched alkyl substituted with an ionizable functional group such as an amine or carboxylic acid, a linear and branched alkoxy (R=—OR), an alkyl comprising —O(CH2CH2O)nCH3, where n is 1-20, an amide —CO—NR1R2, where R1 is any alkyl, organic substituent, R2 is any alkyl, organic substituent, wherein R1 and R2 may be identical or different, —OCO—R, wherein R is any alkyl, organic substituent, an aromatic ring and their substituted analogues, any length and sequence of natural and unnatural amino acids that make up a peptide chain, and —C≡C—R where R is any alkyl, organic substituent.

IPC Classes  ?

  • C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
  • C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
  • C02F 101/12 - Halogens or halogen-containing compounds

2.

Hydrodynamic Methods for Delivering Fluids to Kidney Tissues and Related Materials and Methods

      
Application Number 17859470
Status Pending
Filing Date 2022-07-07
First Publication Date 2023-02-16
Owner
  • Indiana University Research & Technology Corporation (USA)
  • United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
  • Bacallao, Robert
  • Atkinson, Simon
  • Rhodes, George
  • Corridon, Peter

Abstract

The present invention provides methods and materials useful delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the present invention provides methods for delivering saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The delivery methods and materials herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 38/44 - Oxidoreductases (1)
  • A61K 38/45 - Transferases (2)
  • C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

3.

MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES

      
Application Number 17550737
Status Pending
Filing Date 2021-12-14
First Publication Date 2022-10-06
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Pelus, Louis M.
  • Hoggatt, Jonathan
  • Singh, Pratibha

Abstract

This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non−steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

IPC Classes  ?

  • A61K 35/14 - BloodArtificial blood
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • C12N 5/0789 - Stem cellsMultipotent progenitor cells
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61K 38/19 - CytokinesLymphokinesInterferons
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • A61K 31/4035 - Isoindoles, e.g. phthalimide
  • A61K 31/4196 - 1,2,4-Triazoles

4.

SCALABLE ANION CAPTURE MACROCYCLES

      
Application Number US2021054689
Publication Number 2022/081642
Status In Force
Filing Date 2021-10-13
Publication Date 2022-04-21
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Flood, Amar, Hugh
  • Dobscha, James, Robert

Abstract

22n33, where n is 1-20, an amide -CO-NR1R2, where R1is any alkyl, organic substituent, R2is any alkyl, organic substituent, wherein R1and R2 may be identical or different, -OCO-R, wherein R is any alkyl, organic substituent, an aromatic ring and their substituted analogues, any length and sequence of natural and unnatural amino acids that make up a peptide chain, and -C≡C-R where R is any alkyl, organic substituent.

IPC Classes  ?

  • C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
  • B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
  • B01J 41/09 - Organic material

5.

Blood pressure powered auxiliary pump

      
Application Number 16975455
Grant Number 11596783
Status In Force
Filing Date 2019-03-06
First Publication Date 2021-01-21
Grant Date 2023-03-07
Owner Indiana University Research & Technology Corporation (USA)
Inventor Rodefeld, Mark D.

Abstract

Methods and devices for a self-contained device including a hydraulic motor and a hydraulic pump. Preferably, the motor is incorporated either within the interior of the pump, on the exterior of the pump, or a combination of the two. The pump increases the kinetic energy of the fluid by centrifugal means, and in some embodiments is a viscous impeller pump. Applications include building flow systems, industrial processes, and biological circulatory systems.

IPC Classes  ?

  • A61M 60/405 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being hydraulic or pneumatic
  • A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
  • A61M 60/205 - Non-positive displacement blood pumps
  • A61M 60/82 - Magnetic bearings
  • A61M 60/824 - Hydrodynamic or fluid film bearings
  • A61M 60/35 - Medical purposes thereof other than the enhancement of the cardiac output for specific surgeries, e.g. for Fontan procedure
  • A61M 60/882 - Devices powered by the patient, e.g. skeletal muscle powered devices
  • A61M 60/806 - Vanes or blades
  • A61M 60/232 - Centrifugal pumps

6.

Systems and methods for detection of infected websites

      
Application Number 15983093
Grant Number 10880330
Status In Force
Filing Date 2018-05-18
First Publication Date 2018-12-27
Grant Date 2020-12-29
Owner
  • Indiana University Research & Technology Corporation (USA)
  • Georgia Tech Research Corporation (USA)
Inventor
  • Wang, Xiaofeng
  • Yuan, Kan
  • Liao, Xiaojing
  • Beyah, Raheem A.

Abstract

System and method for detecting an infected website are disclosed. A semantic finder receives top-level domains and identifies keywords of the top-level domains representing a predetermined semantics. The keywords are compared with irrelevant bad terms to find at least one irrelevant term. An inconsistency searcher searches the top-level domains and detects at least one fully-qualified domain name carrying the at least one irrelevant term. A context analyzer evaluates context information associated with the irrelevant term, identifies at least one frequently-used term identified in the context information, and determines whether the at least one frequently-used term is unrelated to a generic content of the at least one fully-qualified domain name An irrelevant bad term collector extracts the at least one frequently-used term unrelated to the generic content and adds the extracted frequently-used term to an irrelevant bad term list for detecting the infected website.

IPC Classes  ?

  • H04L 29/06 - Communication control; Communication processing characterised by a protocol
  • G06F 16/9535 - Search customisation based on user profiles and personalisation
  • G06F 21/56 - Computer malware detection or handling, e.g. anti-virus arrangements
  • G06F 40/30 - Semantic analysis
  • G06F 40/205 - Parsing

7.

Volatile organic compound sensors, and methods of making and using the same

      
Application Number 14685231
Grant Number 10107827
Status In Force
Filing Date 2015-04-13
First Publication Date 2018-10-23
Grant Date 2018-10-23
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Agarwal, Mangilal
  • Varahramyan, Khodadad
  • Shrestha, Sudhir
  • Daneshkhah, Ali

Abstract

A biomedical sensor and sensor system for analysis of breath are disclosed. The biomedical sensor can include two layers arranged to swell or contract in a plane perpendicular to an axial direction while being restricted from swelling in the axial direction. The biomedical sensor includes resistance connections to allow measurement of the resistance of each layer and a combined resistance of both layers. The sensor system can include one, two, or three or more sensors, each having a pair of electrodes separated by a gap and one or more layers of composite material located within the gap. the sensor system includes resistance circuits configured to measure changes in resistance between the electrodes. A polypyrrole/polymethyl methacrylate/polyethylene glycol composite material and method of making the same are disclosed.

IPC Classes  ?

  • G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
  • G01N 33/98 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving alcohol, e.g. ethanol in breath
  • G01N 33/64 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving ketones
  • G01N 33/18 - Water
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
  • C08L 79/04 - Polycondensates having nitrogen-containing heterocyclic rings in the main chainPolyhydrazidesPolyamide acids or similar polyimide precursors
  • C08L 33/12 - Homopolymers or copolymers of methyl methacrylate

8.

DNA METHYLATION IN INFLAMMATORY DISEASE

      
Application Number US2017066708
Publication Number 2018/118691
Status In Force
Filing Date 2017-12-15
Publication Date 2018-06-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Mirmira, Raghavendra G.

Abstract

Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA.

IPC Classes  ?

  • A61K 38/00 - Medicinal preparations containing peptides
  • A61P 5/00 - Drugs for disorders of the endocrine system
  • C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
  • C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
  • C40B 50/02 - In silico or mathematical conception of libraries
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

9.

METHODS FOR TREATING HYDROCEPHALUS

      
Application Number US2017068109
Publication Number 2018/119356
Status In Force
Filing Date 2017-12-22
Publication Date 2018-06-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Blazer-Yost, Bonnie Lucille

Abstract

Methods for inhibiting transepithelial ion transport, inhibiting hydrocephalic development, and for treating hydrocephalus are disclosed herein. The methods include administering a potassium channel inhibitor to the individual. In one particular embodiment, the individual is administered the calcium-activated potassium channel inhibitor, fluoxetine.

IPC Classes  ?

  • C07C 217/48 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
  • A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
  • A61P 25/00 - Drugs for disorders of the nervous system

10.

MONOHYDROXYLATED 17ALPHA-HYDROXYPROGESTERONE CAPROATE FOR REDUCING CONTRACTILITY

      
Application Number US2017045265
Publication Number 2018/027013
Status In Force
Filing Date 2017-08-03
Publication Date 2018-02-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Patil, Avinash Shivaputrappa

Abstract

A monohydroxylated 17α-hydroxyprogesterone caproate (HPC-OH), 17α-hydroxyprogesteryl 6-hydroxycaproate, is disclosed herein for reducing uterine contractions, reducing inflammation related to contractility, and preventing preterm birth. Additionally, the use of HPC-OH as a diagnostic is also disclosed.

IPC Classes  ?

  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

11.

QUANTITATIVE PROFILING OF PROGESTERONE METABOLITES FOR THE PREDICTION OF SPONTANEOUS PRETERM DELIVERY

      
Application Number US2017030759
Publication Number 2017/192668
Status In Force
Filing Date 2017-05-03
Publication Date 2017-11-09
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Patil, Dr. Avinash Shivaputrappa

Abstract

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.

IPC Classes  ?

  • C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
  • C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
  • C07J 51/00 - Normal steroids with unmodified cyclopenta[a]hydrophenanthrene skeleton not provided for in groups
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

12.

QUANTITATIVE PROFILING OF PROGESTERONE METABOLITES FOR THE PREDICTION OF SPONTANEOUS PRETERM DELIVERY

      
Document Number 03023242
Status Pending
Filing Date 2017-05-03
Open to Public Date 2017-11-09
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Patil, Avinash Shivaputrappa

Abstract

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.

IPC Classes  ?

  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
  • G01N 33/483 - Physical analysis of biological material
  • G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

13.

Materials and methods to enhance hematopoietic stem cells engraftment procedures

      
Application Number 15592375
Grant Number 11241454
Status In Force
Filing Date 2017-05-11
First Publication Date 2017-10-26
Grant Date 2022-02-08
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Pelus, Louis M.
  • Hoggatt, Jonathan
  • Singh, Pratibha

Abstract

2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • A61K 35/14 - BloodArtificial blood
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • C12N 5/0789 - Stem cellsMultipotent progenitor cells
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61K 38/19 - CytokinesLymphokinesInterferons
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • A61K 31/4035 - Isoindoles, e.g. phthalimide
  • A61K 31/4196 - 1,2,4-Triazoles
  • C12N 5/16 - Animal cells
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • C12N 15/86 - Viral vectors
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

14.

Systems and methods for localized surface plasmon resonance biosensing

      
Application Number 15517383
Grant Number 10858693
Status In Force
Filing Date 2015-10-06
First Publication Date 2017-10-19
Grant Date 2020-12-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Sardar, Rajesh
  • Korc, Murray
  • Joshi, Gayatri K.

Abstract

Biosensors and methods for localized surface plasmon resonance biosensing are disclosed. The biosensor can include a substrate having a substrate surface to which a plurality of localized surface plasmon resonance (LSPR) antennae are affixed. The LSPR antennae can be affixed via an affixation surface of the LSPR antenna. The LSPR antennae can have a functional surface opposite the affixation surface. Each functional surface can be functionalized by a plurality of single-stranded DNA.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • C12Q 1/6825 - Nucleic acid detection involving sensors

15.

DRUGS, PHARMACOGENOMICS AND BIOMARKERS FOR ACTIVE LONGEVITY

      
Application Number US2017023422
Publication Number 2017/165423
Status In Force
Filing Date 2017-03-21
Publication Date 2017-09-28
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • SCRIPPS RESEARCH INSTITUTE (USA)
  • THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL (USA)
Inventor
  • Niculescu, Dr. Alexander B.
  • Petrascheck, Dr. Michael

Abstract

The present disclosure relates generally to genes and biological pathways involved in the active regulation by mood and stress of life expectancy, in all subjects, and separately by gender. Some of these represent a life switch between suicide and longevity. Disclosed are methods for identifying compounds involved in the modulation of active longevity by mood and stress, in particular compounds that modulate the life switch, and thus, modulate active longevity. Also disclosed are methods for increasing active longevity in a subject in general, and modulating the life switch in a subject with psychiatric disorders in particular. Also disclosed are methods for determining biological age score in a subject in general, and predicting lifespan/time to death from all causes in subjects.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

16.

MOBILIZING HIV-INFECTED CELLS FROM LYMPHATIC RESERVOIRS

      
Application Number US2017019897
Publication Number 2017/151586
Status In Force
Filing Date 2017-02-28
Publication Date 2017-09-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Clauss, Matthais, A.
  • Maier, Bernhard, F.

Abstract

Provided herein are methods of treating HIV infection, including retention of HIV+ T cells in viral reservoirs such as lymph nodes. More particularly, provided herein are methods in which an effective amount of a HIV Nef pathway inhibitor (e.g., anti-Nef agent) is administered to a subject in need thereof, whereby administration of the inhibitor treats HIV infection in the subject, decreases retention of HIV+ T cells in lymph nodes, and increases migration of HIV+ T cells from lymph nodes.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 31/12 - Antivirals
  • A61P 31/18 - Antivirals for RNA viruses for HIV
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

17.

EMAPII NEUTRALIZING ANTIBODY LIMITS INFLUENZA A VIRUS (IAV)-INDUCED LUNG INJURY

      
Application Number US2017019069
Publication Number 2017/147258
Status In Force
Filing Date 2017-02-23
Publication Date 2017-08-31
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Bogatcheva, Natalia, V.
  • Clauss, Matthias, A.
  • March, Keith L.

Abstract

EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro- apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches

IPC Classes  ?

  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

18.

COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY

      
Application Number US2017019156
Publication Number 2017/147312
Status In Force
Filing Date 2017-02-23
Publication Date 2017-08-31
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
  • Androphy, Elliot J.
  • Hodgetts, Kevin
  • Calder, Alyssa Nicole

Abstract

Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.

IPC Classes  ?

  • C07D 513/04 - Ortho-condensed systems
  • A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/429 - Thiazoles condensed with heterocyclic ring systems

19.

Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells

      
Application Number 15446552
Grant Number 10308911
Status In Force
Filing Date 2017-03-01
First Publication Date 2017-08-24
Grant Date 2019-06-04
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Hashino, Eri
  • Oxford, Gerry
  • Koehler, Karl R.

Abstract

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

IPC Classes  ?

  • C12N 5/0793 - Neurons
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

20.

LYSOSOMAL ACID LIPASE AND PPAR GAMMA LIGANDS AS AN IMMUNE THERAPIES FOR CANCER TREATMENT

      
Application Number US2017017387
Publication Number 2017/139588
Status In Force
Filing Date 2017-02-10
Publication Date 2017-08-17
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Yan, Cong
  • Du, Hong

Abstract

Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPARγ ligands for treating various cancer patients to promote anti-cancer immunity immunity (suppress MDSCs), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.

IPC Classes  ?

  • C12P 21/00 - Preparation of peptides or proteins
  • A61K 38/00 - Medicinal preparations containing peptides

21.

System and method for non-invasively monitoring autonomic nerve activity

      
Application Number 15490230
Grant Number 11357432
Status In Force
Filing Date 2017-04-18
First Publication Date 2017-08-03
Grant Date 2022-06-14
Owner INDIANA UNIVERSTTY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Chen, Peng-Sheng

Abstract

System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes Identification of persons
  • A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
  • A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
  • A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
  • A61N 1/04 - Electrodes
  • A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
  • A61N 1/362 - Heart stimulators
  • A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

22.

USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES

      
Application Number US2017015389
Publication Number 2017/132536
Status In Force
Filing Date 2017-01-27
Publication Date 2017-08-03
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Pili, Roberto

Abstract

Compositions including combinations of class I histone deacetylase (HDAC) inhibitors and programmed cell death protein 1 (PD-1) inhibitors for enhancing antitumor activity are disclosed. Further disclosed are methods of administering these compositions as immunotherapies for suppressing regulatory T cells in renal cell carcinoma.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/02 - Immunomodulators

23.

METHODS FOR REPAIRING LUNG TISSUE

      
Application Number US2017014577
Publication Number 2017/127810
Status In Force
Filing Date 2017-01-23
Publication Date 2017-07-27
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Petrache, Irina
  • Queini, Houssam
  • March, Keith
  • Broxmeyer, Hal

Abstract

Disclosed are methods for treating chronic obstructive pulmonary disease (COPD), and more particularly emphysema. The present disclosure relates to methods for repairing lung tissue damage caused by COPD by administering AMD3100.

IPC Classes  ?

  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems

24.

COMPOSITION FOR BLOCKING ANGIOGENESIS

      
Application Number US2016062851
Publication Number 2017/091473
Status In Force
Filing Date 2016-11-18
Publication Date 2017-06-01
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Corson, Timothy William
  • Sulaiman, Rania

Abstract

Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.

IPC Classes  ?

  • A61P 27/02 - Ophthalmic agents
  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61P 3/04 - AnorexiantsAntiobesity agents
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

25.

METHODS AND COMPOSITIONS FOR TREATING LUNG DISEASE OF PREMATURITY

      
Application Number US2016057900
Publication Number 2017/070338
Status In Force
Filing Date 2016-10-20
Publication Date 2017-04-27
Owner INDIANA UNIVERSITY RESEARCH &TECHNOLOGY CORPORATION (USA)
Inventor
  • Schwarz, Margaret, Arlene
  • Lee, Dong Il

Abstract

The disclosure relates to methods of treating an infant having or at risk of developing bronchopulmonary dysplasia, including premature infants, by administering an antagonist of endothelial monocyte-activating polypeptide II (EMAP II) to the infant.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 9/12 - AerosolsFoams
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

26.

ANTIBIOTIC GEL FORMULATION AND METHODS OF PREPARING THE ANTIBIOTIC GEL FORMULATION

      
Application Number US2016048157
Publication Number 2017/040107
Status In Force
Filing Date 2016-08-23
Publication Date 2017-03-09
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Yassen, Ghaeth H, Dr.
  • Platt, Jeffrey A, Dr.
  • Gregory, Richard L, Dr.

Abstract

Antibiotic gel formulations for use in dental applications are disclosed. More particularly, the present disclosure is directed to antibiotic gel formulations including low concentrations of antibiotics that are capable of killing root canal pathogens without harming the stem cells inside the root canal. Additionally, the present disclosure is directed to delivery systems and methods for applying the antibiotic gel formulations into a subject's intracanal region.

IPC Classes  ?

27.

DELIVERY SYSTEMS FOR APPLICATION OF ANTIBIOTIC GEL FORMULATION

      
Application Number US2016048165
Publication Number 2017/040110
Status In Force
Filing Date 2016-08-23
Publication Date 2017-03-09
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Yassen, Dr. Ghaeth H.
  • Platt, Dr. Jeffrey A.
  • Gregory, Dr. Richard L.

Abstract

Antibiotic gel formulations for use in dental applications are disclosed. More particularly, the present disclosure is directed to antibiotic gel formulations including low concentrations of antibiotics that are capable of killing root canal pathogens without harming the stem cells inside the root canal. Additionally, the present disclosure is directed to delivery systems and methods for applying the antibiotic gel formulations into a subject's intracanal region.

IPC Classes  ?

  • A61K 6/02 - Use of preparations for artificial teeth, for filling or for capping teeth

28.

CELL-FREE METHYLATED AND UNMETHYLATED DNA IN DISEASES RESULTING FROM ABNORMALITIES IN BLOOD GLUCOSE LEVELS

      
Application Number US2016043407
Publication Number 2017/015497
Status In Force
Filing Date 2016-07-21
Publication Date 2017-01-26
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • UNIVERSITÉ LIBRE DE BRUXELLES (Belgium)
Inventor
  • Mirmira, Raghavendra G.
  • Tersey, Sarah A.
  • Eizirik, Decio Laks
  • Fuks, Francois

Abstract

Disclosed herein are compositions and methods for determining new-onset type 1 diabetes, methylation-specific polymerase chain reaction assays for determining new-onset type 1 diabetes, methods for distinguishing between type 1 diabetes and type 2 diabetes, methods for dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes and methylation-specific polymerase chain reaction assays for determining dysglycemia in obese adolescent subjects including obese adolescent subjects having type 2 diabetes.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

29.

TRANSGENIC PIGS WITH GENETIC MODIFICATIONS OF SLA

      
Application Number US2016039279
Publication Number 2016/210280
Status In Force
Filing Date 2016-06-24
Publication Date 2016-12-29
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Tector Iii, A., Joseph

Abstract

The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Transgenic pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.

IPC Classes  ?

  • A01K 67/027 - New or modified breeds of vertebrates
  • A61K 35/407 - LiverHepatocytes
  • C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/877 - Techniques for producing new mammalian cloned embryos

30.

PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT

      
Document Number 02988578
Status Pending
Filing Date 2016-06-10
Open to Public Date 2016-12-15
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Niculescu, Alexander

Abstract

Biomarkers and methods for screening expression levels of the biomarkers for predicting suicidality (referred herein to suicidal ideation and actions, future hospitalizations and suicide completion) are disclosed. Also disclosed are quantitative questionnaires and mobile applications for assessing affective state and for assessing socio-demographic and psychological suicide risk factors, and their use to compute scores that can predict suicidality. Finally, an algorithm that combines biomarkers and computer apps for identifying subjects who are at risk for committing suicide is disclosed, as well as methods to mitigate and prevent suicidality based on the biomarkers and computer apps.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
  • G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

31.

PREDICTING SUICIDALITY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT

      
Application Number US2016036985
Publication Number 2016/201299
Status In Force
Filing Date 2016-06-10
Publication Date 2016-12-15
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Niculescu, Dr. Alexander

Abstract

Biomarkers and methods for screening expression levels of the biomarkers for predicting suicidality (referred herein to suicidal ideation and actions, future hospitalizations and suicide completion) are disclosed. Also disclosed are quantitative questionnaires and mobile applications for assessing affective state and for assessing socio-demographic and psychological suicide risk factors, and their use to compute scores that can predict suicidality. Finally, an algorithm that combines biomarkers and computer apps for identifying subjects who are at risk for committing suicide is disclosed, as well as methods to mitigate and prevent suicidality based on the biomarkers and computer apps.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
  • G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions

32.

PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF

      
Application Number US2016035212
Publication Number 2016/196591
Status In Force
Filing Date 2016-06-01
Publication Date 2016-12-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Zhong-Yin
  • He, Rongjun

Abstract

Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

IPC Classes  ?

  • A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
  • A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
  • A61K 31/10 - SulfidesSulfoxidesSulfones
  • C07C 317/02 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
  • C07C 317/08 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
  • C07C 317/18 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

33.

SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USES THEREOF

      
Application Number US2016035181
Publication Number 2016/196569
Status In Force
Filing Date 2016-06-01
Publication Date 2016-12-08
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Zhong-Yin
  • He, Rongjun

Abstract

Small molecule compounds derived from α-sulfophenylacetic amide (SPAA) are provided as novel sulfonic acid based pTyr mimetics. These compounds effectively inhibit a variety of protein tyrosine phosphatases (PTPs), such as mPTPA, mPTPB, LMWPTP, and Laforin. Use of these compounds as pharmaceutical agents for treating diseases associated with abnormal protein tyrosine phosphatase activity is also provided.

IPC Classes  ?

  • A61K 8/42 - Amides
  • A61K 8/46 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K 31/10 - SulfidesSulfoxidesSulfones

34.

Macrocycle with repeating triazole-carbazole units

      
Application Number 15170677
Grant Number 10202395
Status In Force
Filing Date 2016-06-01
First Publication Date 2016-12-01
Grant Date 2019-02-12
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Flood, Amar
  • Hirsch, Brandon E.
  • Lee, Semin
  • Tait, Steven L.
  • Dobscha, James

Abstract

Disclosed herein are compositions of tricarbazole triazolophane (tricarb) of Formulas (I), (II) and (III): 18), alkyl-substituted phenyl derivatives, and substituted glycol derivatives, or a combination thereof. The disclosure presents examples of thin films composed of the same as well as methods of binding anions from the same.

IPC Classes  ?

  • C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
  • C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
  • B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
  • B01J 45/00 - Ion-exchange in which a complex or a chelate is formedUse of material as complex or chelate forming ion-exchangersTreatment of material for improving the complex or chelate forming ion-exchange properties
  • B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
  • B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
  • B01J 41/04 - Processes using organic exchangers
  • C02F 1/42 - Treatment of water, waste water, or sewage by ion-exchange
  • B01J 41/09 - Organic material
  • C02F 101/12 - Halogens or halogen-containing compounds
  • C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated

35.

METHODS AND SYSTEMS FOR PATIENT SPECIFIC IDENTIFICATION AND ASSESSMENT OF OCULAR DISEASE RISK FACTORS AND TREATMENT EFFICACY

      
Application Number US2016033521
Publication Number 2016/191277
Status In Force
Filing Date 2016-05-20
Publication Date 2016-12-01
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Harris, Alon
  • Guidoboni, Giovanna

Abstract

This disclosure provides systems and methods for patient-specific identification and assessment of ocular disease risk factors and efficacy of various treatments. The systems and methods can include mathematically modeling an expected normal patient-specific value of one or more clinically observable properties using a patient-specific mathematical model that can be calibrated with patient-specific data. The expected normal patient-specific value can be compared with a measured patient-specific value. A greater difference between the expected and measured patient-specific values can correlate to greater ocular vasculature abnormalities.

IPC Classes  ?

  • A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes

36.

METHODS OF TARGETING APE1/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES

      
Document Number 02986248
Status In Force
Filing Date 2016-05-05
Open to Public Date 2016-11-24
Grant Date 2023-09-26
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Kelley, Mark R.
  • Fishel, Melissa

Abstract

Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APEl/Ref-1) are disclosed. More particularly, methods for inhibiting APEl/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin

37.

METHODS OF TARGETING APE1/REF-1 TO INHIBIT HYPOXIA SIGNALING GENES

      
Application Number US2016030904
Publication Number 2016/186853
Status In Force
Filing Date 2016-05-05
Publication Date 2016-11-24
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Kelley, Mark R.
  • Fishel, Melissa

Abstract

Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APEl/Ref-1) are disclosed. More particularly, methods for inhibiting APEl/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin

38.

SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF

      
Application Number US2016032473
Publication Number 2016/187046
Status In Force
Filing Date 2016-05-13
Publication Date 2016-11-24
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Jian-Ting
  • Liu, Jing-Yuan

Abstract

Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structure.

IPC Classes  ?

  • A61K 31/4245 - Oxadiazoles
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • C07D 271/08 - 1,2,5-OxadiazolesHydrogenated 1,2,5-oxadiazoles

39.

CELL CULTURE SYSTEMS FOR PRODUCING IL-33 INDUCED T9 CELLS AND METHODS OF USING THE CELLS

      
Application Number US2016031310
Publication Number 2016/182944
Status In Force
Filing Date 2016-05-06
Publication Date 2016-11-17
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Paczesny, Sophie

Abstract

Cell culture systems for producing IL-33 induced T9 cells and methods of using the IL-33 induced T9 cells (T9IL-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (HCT) and/or treating graft-versus-host disease (GVHD) are disclosed herein. Further, methods of using the T9IL-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment.

IPC Classes  ?

  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
  • C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

40.

ULTRASOUND CATHETER

      
Application Number US2016020866
Publication Number 2016/141281
Status In Force
Filing Date 2016-03-04
Publication Date 2016-09-09
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Akingba, A., George

Abstract

A system and a method for disrupting an occlusion within a blood vessel is provided The system includes an elongated catheter body having a proximal portion, a distal portion, and a first lumen. The system further includes an ultrasound transmitter extending longitudinally through the first lumen of the catheter body and having a proximal end and a distal end. The system further includes a positioning mechanism located at a distal end of the catheter body. The positioning mechanism has a first retracted position and a second deployed position, and the positioning mechanism is radially expandable from the first retracted position to the second deployed position to position the catheter in the blood vessel.

IPC Classes  ?

  • A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
  • A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
  • A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters

41.

A TH17-PRONE CD146+CCR5+ T-CELL POPULATION AS AN EARLY MARKER OF INTESTINAL GRAFT-VERSUS-HOST DISEASE

      
Application Number US2016015352
Publication Number 2016/123334
Status In Force
Filing Date 2016-01-28
Publication Date 2016-08-04
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Paczesny, Sophie

Abstract

Th17-prone CD146+CCR5+ T-cell population as an early biomarker of intestinal graft-versus-host disease and its use for determining prognosis of intestinal GVHD before the clinical signs are apparent are disclosed.

IPC Classes  ?

  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent

42.

CULTURE CONDITIONS THAT ALLOW ZYMOMONAS MOBILIS TO ASSIMILATE N2 GAS AS A NITROGEN SOURCE DURING BIO-ETHANOL PRODUCTION

      
Application Number US2015067100
Publication Number 2016/109286
Status In Force
Filing Date 2015-12-21
Publication Date 2016-07-07
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Mckinlay, James
  • Posto, Amanda
  • Lasarre, Breah
  • Kremer, Timothy

Abstract

Chemically defined culture medium and culture conditions that allow bacteria to assimilate dinitrogen gas (N2) as a nitrogen source during bio-ethanol production are disclosed herein. Methods of bioethanol production using the chemically defined culture medium and culture conditions are also disclosed.

IPC Classes  ?

  • C12P 7/06 - Ethanol, i.e. non-beverage
  • C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
  • C12P 7/08 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate

43.

METHODS FOR DETECTING SINUSOIDAL OBSTRUCTIVE SYNDROME (SOS)

      
Application Number US2015057393
Publication Number 2016/069483
Status In Force
Filing Date 2015-10-26
Publication Date 2016-05-06
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Paczesny, Sophie

Abstract

Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.

IPC Classes  ?

  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 30/72 - Mass spectrometers
  • A61B 5/00 - Measuring for diagnostic purposes Identification of persons

44.

SYSTEM AND METHODS FOR NON-INVASIVELY CONTROLLING AUTONOMIC NERVE ACTIVITY

      
Document Number 02965149
Status In Force
Filing Date 2015-10-20
Open to Public Date 2016-04-28
Grant Date 2023-10-10
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Chen, Peng-Sheng

Abstract

System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

IPC Classes  ?

  • A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
  • A61B 5/294 - Bioelectric electrodes therefor specially adapted for particular uses for nerve conduction study [NCS]
  • A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves

45.

SYSTEM AND METHODS FOR NON-INVASIVELY MONITORING AUTONOMIC NERVE ACTIVITY USING SKIN

      
Application Number US2015056419
Publication Number 2016/064843
Status In Force
Filing Date 2015-10-20
Publication Date 2016-04-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Chen, Peng-Sheng

Abstract

System and methods for monitoring and/or controlling nerve activity in a subject are provided. In one embodiment, a system includes electrodes configured to be placed proximate to a subject's skin, and a signal detector configured to detect electrical signals using the electrodes. The system also includes a signal processor configured to receive the electrical signals from the signal detector, and apply a filter to the received electrical signals to generate filtered signals, the filter configured to attenuate at least signals having frequencies corresponding to heart muscle activity during a heartbeat. The signal processor is also configured to identify a skin nerve activity using the filtered signals, estimate a sympathetic nerve activity using the identified skin nerve activity, and further to generate a report indicative of the estimated sympathetic nerve activity. In some aspects, the system further includes a signal generator to deliver the electrical stimulation to the subject's skin.

IPC Classes  ?

  • A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
  • A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
  • A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves

46.

TRIPLE TRANSGENIC PIGS SUITABLE FOR XENOGRAFT

      
Document Number 02965550
Status Pending
Filing Date 2015-10-21
Open to Public Date 2016-04-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Tector, Joseph A.

Abstract

[0146] The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Knockout pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.

IPC Classes  ?

  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
  • A61L 27/38 - Animal cells
  • C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
  • C12N 15/54 - Transferases (2)
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

47.

THE ROLE OF A CLUSTER OF LONG NONCODING RNA TRANSCRIPTS IN PROTECTING THE HEART FROM PATHOLOGICAL HYPERTROPHY

      
Application Number IB2015058041
Publication Number 2016/063202
Status In Force
Filing Date 2015-10-19
Publication Date 2016-04-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Chang, Ching-Pin

Abstract

Nucleic acids encoding modified myosin heavy-chain-associated RNA transcripts are provided. The modified myosin heavy-chain-associated RNA transcripts belongs to a cluster of long noncoding RNAs (lncRNA) and bind to chromatin remodeler Brg1 to inhibit Brg1's genomic targeting and gene regulation function. The modified myosin heavy-chain- associated RNA transcripts expressed in an individual inhibit Brg1's gene regulation function and protect the heart of the individual from myopathy and failure. One of the modified heavy- chain-associated RNAs is a 400 base pair fragment segmented from a natural 779 base pair sequence of Mhrt (Mhrt779) and has the same cardioprotective effects as the Mhrt779.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

48.

TRIPLE TRANSGENIC PIGS SUITABLE FOR XENOGRAFT

      
Application Number US2015056730
Publication Number 2016/065046
Status In Force
Filing Date 2015-10-21
Publication Date 2016-04-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Tector Iii, A., Joseph

Abstract

The application provides methods of improving a rejection related symptom, reducing premature separation and methods of producing a compound of interest with an altered epitope profile are provided. Knockout pigs with a disrupted gene or genes, and porcine organs, tissues, and cells therefrom are provided.

IPC Classes  ?

  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals

49.

SYSTEMS AND METHODS FOR LOCALIZED SURFACE PLASMON RESONANCE BIOSENSING

      
Application Number US2015054174
Publication Number 2016/057474
Status In Force
Filing Date 2015-10-06
Publication Date 2016-04-14
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Sardar, Rajesh
  • Korc, Murray
  • Joshi, Gayatri, K.

Abstract

Biosensors and methods for localized surface plasmon resonance biosensing are disclosed. The biosensor can include a substrate having a substrate surface to which a plurality of localized surface plasmon resonance (LSPR) antennae are affixed. The LSPR antennae can be affixed via an affixation surface of the LSPR antenna. The LSPR antennae can have a functional surface opposite the affixation surface. Each functional surface can be functionalized by a plurality of single-stranded DNA.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01J 3/42 - Absorption spectrometryDouble-beam spectrometryFlicker spectrometryReflection spectrometry

50.

Methods and systems for tissue damage identification and quantification

      
Application Number 14851799
Grant Number 11211166
Status In Force
Filing Date 2015-09-11
First Publication Date 2016-03-17
Grant Date 2021-12-28
Owner Indiana University Research & Technology Corp (USA)
Inventor
  • Mckinley, Todd O.
  • Steenburg, Scott D.

Abstract

Example embodiments are described that relate to the analysis of tissue damage in an injured patient. Example embodiments are methods and systems for collecting medical imaging data, identifying tissue damage in the medical imaging data, analyzing the tissue damage shown in the medical imaging data, and/or quantifying the tissue damage shown in the medical imaging data. The disclosed methods allow for determining a risk for multiple organ failure and systemic inflammation in a multiply injured patient.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

51.

Materials and methods to enhance hematopoietic stem cells engraftment procedures

      
Application Number 14638676
Grant Number 09675641
Status In Force
Filing Date 2015-03-04
First Publication Date 2016-02-04
Grant Date 2017-06-13
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Pelus, Louis M.
  • Hoggatt, Jonathan
  • Singh, Pratibha

Abstract

2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

IPC Classes  ?

  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
  • C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 35/14 - BloodArtificial blood
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • C12N 5/0789 - Stem cellsMultipotent progenitor cells
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61K 38/19 - CytokinesLymphokinesInterferons
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • A61K 31/4035 - Isoindoles, e.g. phthalimide
  • A61K 31/4196 - 1,2,4-Triazoles
  • C12N 5/16 - Animal cells
  • C12N 15/86 - Viral vectors
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

52.

SYSTEMS AND METHODS FOR CONTROLLING A VENTRICULAR RATE DURING ATRIAL FIBRILLATION

      
Application Number US2015041979
Publication Number 2016/014938
Status In Force
Filing Date 2015-07-24
Publication Date 2016-01-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Chen, Peng-Sheng

Abstract

Systems and methods for controlling a ventricular rate during atrial fibrillation are provided. In some aspects, a method includes selecting a treatment protocol based on a determined condition of a subject, the treatment protocol comprising intermittent periods of electrical stimulation separated by periods of non-stimulation. The method also includes applying an electrical stimulation, according to the selected the treatment protocol, using an electrical source and at least one electrode positioned at locations associated with a vagal nerve of the subject to control a ventricular rate during atrial fibrillation.

IPC Classes  ?

  • A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential

53.

Methods of diagnosing, treating and monitoring diabetic retinopathy

      
Application Number 14767111
Grant Number 10132815
Status In Force
Filing Date 2014-02-07
First Publication Date 2015-12-31
Grant Date 2018-11-20
Owner Indiana University Research & Technology Corporation (USA)
Inventor Gangaraju, Shekhar Raja

Abstract

Methods for the treatment and monitoring of diabetic retinopathy are provided. More specifically, the method for the treatment of diabetic retinopathy comprises administering to an individual suspected of having diabetic retinopathy a composition comprising an agent that inhibits the activity or expression of EMAPII or CXCR3. Methods for diagnosing and monitoring the progression of diabetic retinopathy in an individual, or monitoring the efficacy of a therapy for diabetic retinopathy are provided. More specifically, the method comprises determining the levels of EMAPII in a biological sample from an individual and comparing them to a control or reference sample, or a chronological sample from the individual.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 14/52 - CytokinesLymphokinesInterferons
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

54.

Poly-cyanostilbene macrocycles

      
Application Number 14767570
Grant Number 09701621
Status In Force
Filing Date 2014-02-13
First Publication Date 2015-12-31
Grant Date 2017-07-11
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Flood, Amar H.
  • Lee, Semin
  • Mcdonald, Kevin

Abstract

The present disclosure concerns synthesis and anion binding features of poly-cyanostilbene macrocycles of Formula (I):

IPC Classes  ?

  • C07C 255/47 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
  • C07D 213/57 - Nitriles
  • C07D 249/04 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles
  • C07F 7/08 - Compounds having one or more C—Si linkages
  • C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages

55.

SYSTEM AND METHOD FOR EXTRACTING TISSUE SAMPLES

      
Application Number US2015035152
Publication Number 2015/191749
Status In Force
Filing Date 2015-06-10
Publication Date 2015-12-17
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Gutwein, Luke, G.
  • Sood, Rajiv
  • Tholpady, Sunil, S.

Abstract

A method and apparatus for extracting tissue samples are disclosed herein. An example apparatus disclosed herein includes a first sidewall and a second sidewall spaced apart from the first sidewall. The example apparatus also includes a track to receive a blade between the first sidewall and the second sidewall. The track is to guide the blade to penetrate skin of a patient to a predetermined depth of invasion.

IPC Classes  ?

  • A61B 10/02 - Instruments for taking cell samples or for biopsy

56.

Dielectric electrolyte measurement device

      
Application Number 14648497
Grant Number 10724986
Status In Force
Filing Date 2013-11-27
First Publication Date 2015-10-29
Grant Date 2020-07-28
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Izadian, Afshin
  • Bacallao, Robert L.

Abstract

A system, device and apparatus for measuring electrolytes, where an electrical charge is applied to a measurement portion to draw ions from a liquid to a gel-solution via at least one electric field. The gel-solution containing the extracted ions is excited with light of a predetermined wavelength from an emitter. A receiver detects the illumination of the ions as a result of the excited gel-solution, and a processor converts the detected intensities of the illumination to a biologically useful value representing ionic concentration.

IPC Classes  ?

57.

Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity

      
Application Number 14417471
Grant Number 09447103
Status In Force
Filing Date 2013-07-27
First Publication Date 2015-07-16
Grant Date 2016-09-20
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Lu, Hau
  • Zeng, Shelya
  • Zhang, Qi
  • Ye, Qizhuang
  • Ding, Derong

Abstract

+/+ cells. This INZ analog exhibited a much lower effect on p53-null H1299 cells and importantly no toxicity towards normal human p53-containing WI-38 cells. Those results also reveal key chemical features for INZ activity, and identify the newly synthesized INZ analog 37 as a better small molecule for further development of anti-cancer therapies.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
  • A61K 33/24 - Heavy metalsCompounds thereof
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

58.

Methods of modulating thrombocytopenia and modified transgenic pigs

      
Application Number 14491183
Grant Number 09420770
Status In Force
Filing Date 2014-09-19
First Publication Date 2015-05-14
Grant Date 2016-08-23
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Tector, Iii, Alfred Joseph
  • Burlak, Christopher

Abstract

The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.

IPC Classes  ?

  • G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
  • A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
  • A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
  • A01K 67/027 - New or modified breeds of vertebrates
  • A61K 35/407 - LiverHepatocytes

59.

Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells

      
Application Number 14398664
Grant Number 09624468
Status In Force
Filing Date 2013-05-06
First Publication Date 2015-05-07
Grant Date 2017-04-18
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Hashino, Eri
  • Oxford, Gerry
  • Koehler, Karl R.

Abstract

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

IPC Classes  ?

  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 5/0793 - Neurons
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

60.

High surface area nano-structured graphene composites and capacitive devices incorporating the same

      
Application Number 14535473
Grant Number 09859063
Status In Force
Filing Date 2014-11-07
First Publication Date 2015-03-26
Grant Date 2018-01-02
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Xie, Jian
  • Wang, Meixian

Abstract

A carbon composite material, including a plurality of spaced graphene sheets, each respective sheet having opposed generally planar surfaces, and a plurality of functionalized carbonaceous particles. At least some functionalized carbonaceous particles are disposed between any two adjacent graphene sheets, and each respective at least some functionalized carbonaceous particle is attached to both respective any two adjacent graphene sheets. Each respective graphene sheet comprises at least one layer of graphene and at least portions of respective any two adjacent graphene sheets are oriented substantially parallel with one another.

IPC Classes  ?

  • H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
  • B32B 5/16 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer formed of particles, e.g. chips, chopped fibres, powder
  • B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
  • H01G 11/34 - Carbon-based characterised by carbonisation or activation of carbon
  • B05D 1/18 - Processes for applying liquids or other fluent materials performed by dipping
  • B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
  • B05D 3/10 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by other chemical means
  • B32B 38/08 - Impregnating
  • H01G 11/52 - Separators
  • B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
  • B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
  • B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
  • B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
  • B32B 3/08 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by features of form at particular places, e.g. in edge regions characterised by added members at particular parts
  • B82Y 40/00 - Manufacture or treatment of nanostructures
  • C01B 3/00 - HydrogenGaseous mixtures containing hydrogenSeparation of hydrogen from mixtures containing itPurification of hydrogen
  • B01J 21/18 - Carbon
  • B01J 23/42 - Platinum
  • B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
  • B01D 53/62 - Carbon oxides

61.

HYDRODYNAMIC METHOD AND APPARATUS FOR DELIVERING FLUIDS TO KIDNEY TISSUES

      
Application Number US2014053681
Publication Number 2015/031883
Status In Force
Filing Date 2014-09-02
Publication Date 2015-03-05
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Bacallao, Robert

Abstract

The invention provides a catheter and control box apparatus and related methods that are useful in delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the invention provides a catheter that stabilizes fluid flow within a vein to deliver a volume, pressure charge of saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The catheter and control box apparatus and related methods described herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

IPC Classes  ?

  • C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
  • A61K 38/18 - Growth factorsGrowth regulators

62.

HYDRODYNAMIC DELIVERY OF FLUIDS TO KIDNEY TISSUE

      
Document Number 02959189
Status In Force
Filing Date 2014-09-02
Open to Public Date 2015-03-05
Grant Date 2022-04-12
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Bacallao, Robert

Abstract

The invention provides a catheter and control box apparatus and related methods that are useful in delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the invention provides a catheter that stabilizes fluid flow within a vein to deliver a volume, pressure charge of saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The catheter and control box apparatus and related methods described herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

IPC Classes  ?

  • A61M 25/10 - Balloon catheters
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
  • A61M 25/14 - Arrangement or shape of fluid flow passages, e.g. of plural fluid passages
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

63.

SHP2 INHIBITORS AND METHODS OF TREATING AUTOIMMUNE AND/OR GLOMERULONEPHRITIS-ASSOCIATED DISEASES USING SHP2 INHIBITORS

      
Application Number US2014045318
Publication Number 2015/003094
Status In Force
Filing Date 2014-07-02
Publication Date 2015-01-08
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventor
  • Zhang, Zhong-Yin
  • Kontaridis, Maria
  • Zeng, Li-Fan
  • Wang, Jianxun

Abstract

Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).

IPC Classes  ?

  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61P 35/00 - Antineoplastic agents

64.

PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES

      
Application Number US2014041337
Publication Number 2014/197820
Status In Force
Filing Date 2014-06-06
Publication Date 2014-12-11
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Blazer-Yost, Bonnie

Abstract

Compositions and methods are described herein for the treatment of cystic diseases using PPARγ modulators. In particular, compositions and methods are described herein for the treatment of cystic diseases using low doses of PPARγ modulators.

IPC Classes  ?

  • A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives

65.

Methods for the diagnosis and treatment of neurological disorders

      
Application Number 14354796
Grant Number 10176299
Status In Force
Filing Date 2012-11-13
First Publication Date 2014-11-13
Grant Date 2019-01-08
Owner
  • RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (USA)
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Torres, Elizabeth B.
  • Jose-Valenzuela, Jorge

Abstract

The present invention provides objective methods of diagnosis and behavioral treatments of neurological disorders such as autism spectral disorders and Parkinson's disease.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes Identification of persons
  • A61B 5/16 - Devices for psychotechnicsTesting reaction times
  • A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
  • G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • H04L 29/06 - Communication control; Communication processing characterised by a protocol
  • G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

66.

COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES

      
Document Number 02947838
Status Pending
Filing Date 2014-05-06
Open to Public Date 2014-11-13
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Republic of Korea)
Inventor
  • Corson, Timothy W.
  • Basavarajappa, Halesha D.
  • Seo, Seung-Yong
  • Lee, Bit
  • Fei, Xiang

Abstract

Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.

IPC Classes  ?

  • C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring

67.

COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES

      
Application Number US2014036965
Publication Number 2014/182695
Status In Force
Filing Date 2014-05-06
Publication Date 2014-11-13
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Republic of Korea)
Inventor
  • Corson, Timothy W.
  • Basavarajappa, Halesha D.
  • Seo, Seung-Yong
  • Lee, Bit
  • Fei, Xiang

Abstract

Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.

IPC Classes  ?

  • C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
  • C07D 311/74 - Benzo [b] pyrans, hydrogenated in the carbocyclic ring
  • A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

68.

HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2)

      
Document Number 02944198
Status In Force
Filing Date 2014-04-25
Open to Public Date 2014-10-30
Grant Date 2021-11-16
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Zhong-Yin
  • Zeng, Li-Fan

Abstract

Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

IPC Classes  ?

  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61P 35/00 - Antineoplastic agents

69.

HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2)

      
Application Number US2014035435
Publication Number 2014/176488
Status In Force
Filing Date 2014-04-25
Publication Date 2014-10-30
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Zhong-Yin
  • Zeng, Li-Fan

Abstract

Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

IPC Classes  ?

  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61P 35/00 - Antineoplastic agents

70.

COMPOSITIONS AND METHODS FOR DIAGNOSING LUNG CANCERS

      
Application Number US2014034343
Publication Number 2014/172447
Status In Force
Filing Date 2014-04-16
Publication Date 2014-10-23
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Du, Hong
  • Yan, Cong

Abstract

The present invention provides diagnostics for identifying and distinguishing various types of lung cancers using serum and/or bronchioalveolar lavage fluid. Signatures of secretory proteins are used to identify and distinguish lung cancers. The biomarker signatures may also be used to separate lung cancers from other inflammatory diseases, monitor progression, or assess treatment efficacy.

IPC Classes  ?

  • C12Q 1/56 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
  • G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

71.

Directional guide catheter assembly

      
Application Number 14209291
Grant Number 09623207
Status In Force
Filing Date 2014-03-13
First Publication Date 2014-09-18
Grant Date 2017-04-18
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Akingba, A. George
  • Fischer, Jr., Frank J.

Abstract

A guide catheter assembly includes an outer sheath and an inner catheter disposed, at least partially, within the outer sheath. A tether tethers the inner catheter to the outer sheath. The guide catheter assembly has a first configuration where the tether is untensioned and distal ends of the outer sheath and inner catheter are pointing in a first direction. In a second configuration of the guide catheter assembly, the tether is tensioned, the distal end of the outer sheath is pointing in the first direction, the distal end of the inner catheter is pointing in a second direction that is different from the first direction, and the tether is oriented at an angle different from both the first direction and the second direction.

IPC Classes  ?

  • A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
  • A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
  • A61M 25/00 - CathetersHollow probes

72.

Real-time soot measurement in a diesel particulate filter

      
Application Number 14182039
Grant Number 09151205
Status In Force
Filing Date 2014-02-17
First Publication Date 2014-08-21
Grant Date 2015-10-06
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Huq, Ragibul
  • Anwar, Sohel

Abstract

Methods and apparatus for detecting the filtering state of a filter, such as a particulate filter. Some embodiments include one or more capacitive sensors that provide a signal corresponding to the filtered state of the filter with a change in measured capacitance. A novel ECT based sensing technique for soot load estimation in a diesel particulate filter is presented. The sensing technology is based on principle that deposited soot thickness inside DPF causes a variation in the dielectric constant which has a direct impact on the capacitance of ECT system and its output voltage. The sensor can be built into the DPF outer shell as indicated in the design. The simulation results demonstrate that there is a direct relationship between the amount of soot load in the DPF and the output voltage of the ECT system which can be used to estimate the soot load.

IPC Classes  ?

  • F01N 11/00 - Monitoring or diagnostic devices for exhaust-gas treatment apparatus
  • G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials

73.

METHODS OF DIAGNOSING, TREATING AND MONITORING DIABETIC RETINOPATHY

      
Application Number US2014015257
Publication Number 2014/126796
Status In Force
Filing Date 2014-02-07
Publication Date 2014-08-21
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Gangaraju, Rajashekhar

Abstract

Methods for the treatment and monitoring of diabetic retinopathy are provided. More specifically, the method for the treatment of diabetic retinopathy comprises administering to an individual suspected of having diabetic retinopathy a composition comprising an agent that inhibits the activity or expression of EMAPII or CXCR3. Methods for diagnosing and monitoring the progression of diabetic retinopathy in an individual, or monitoring the efficacy of a therapy for diabetic retinopathy are provided. More specifically, the method comprises determining the levels of EMAPII in a biological sample from an individual and comparing them to a control or reference sample, or a chronological sample from the individual.

IPC Classes  ?

  • A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • A61P 11/00 - Drugs for disorders of the respiratory system

74.

SYSTEM AND METHOD FOR NON-INVASIVE AUTONOMIC NERVE ACTIVITY MONITORING

      
Application Number US2013073817
Publication Number 2014/089549
Status In Force
Filing Date 2013-12-09
Publication Date 2014-06-12
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Chen, Peng-Sheng
  • Lin, Shien-Fong

Abstract

A system and method for monitoring nerve activity in a subject. The system includes a plurality of electrodes placed in proximity to skin of the subject, an amplifier electrically connected to the electrodes and configured to generate a plurality of amplified signals corresponding to electrical signals received from the subject through the electrodes, and a signal processor. The signal processor applies a high-pass filter to the amplified signals to generate filtered signals from the amplified signals, identifies autonomic nerve activity in the plurality of filtered signals; and generates an output signal corresponding to the filtered signals. The high-pass filter attenuates a plurality of the amplified signals having frequencies that correspond to heart muscle activity during a heartbeat.

IPC Classes  ?

  • A61B 5/04 - Measuring bioelectric signals of the body or parts thereof

75.

System and method for pyeloplasty internal-external stent

      
Application Number 14071222
Grant Number 09433765
Status In Force
Filing Date 2013-11-04
First Publication Date 2014-05-08
Grant Date 2016-09-06
Owner Indiana University Research & Technology Corporation (USA)
Inventor Whittam, Benjamin

Abstract

A system and method is provided for the deployment of a ureter between a kidney and a bladder. A stent includes a flexible internal drainage portion, a retention portion, and an external drainage portion. The external drainage portion includes a sharpened tip configured to be passed from through a renal pelvis and out the side of a patient's body from inside the ureter. The stent is arranged to be removable by pulling the external drainage portion and thereby removing the stent out the side of the body.

IPC Classes  ?

  • A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
  • A61M 27/00 - Drainage appliances for wounds, or the like

76.

DOUBLE KNOCKOUT (GT/CMAH-KO) PIGS, ORGANS AND TISSUES

      
Application Number US2013066387
Publication Number 2014/066505
Status In Force
Filing Date 2013-10-23
Publication Date 2014-05-01
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Tector, A., Joseph

Abstract

The invention provides double knockout transgenic pigs (GT/CMAH-KO pigs) lacking expression of any functional aGAL and CMAH. Double knockout GT/CMAH-KO transgenic organs, tissues and cells are also provided. Methods of making and using the GT/CMAH-KO pigs and tissue are also provided.

IPC Classes  ?

  • A01K 67/027 - New or modified breeds of vertebrates
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/22 - Ribonucleases
  • C12N 9/40 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
  • C12N 15/877 - Techniques for producing new mammalian cloned embryos

77.

INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES

      
Application Number US2013063278
Publication Number 2014/055768
Status In Force
Filing Date 2013-10-03
Publication Date 2014-04-10
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Zhang, Zhong-Yin
  • Zhang, Sheng

Abstract

Novel protein tyrosine phosphatase (PTP) inhibitor compounds synthesized from phosphonodifluoromethyl phenylalanine (F2Pmp) are provided. Use of these compounds for inhibiting a PTP enzyme (such as PTP-MEG2), as well as treating a disease, disorder, or condition associated with inappropriate activity of a PTP (such as type 2 diabetes), is also provided.

IPC Classes  ?

  • C07F 9/36 - Amides thereof
  • C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
  • A61K 31/16 - Amides, e.g. hydroxamic acids
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

78.

MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS

      
Application Number US2013059529
Publication Number 2014/043397
Status In Force
Filing Date 2013-09-12
Publication Date 2014-03-20
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Johnson, Raymond, M.

Abstract

Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult HIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control. Those comparisons suggest that HIV KLS is a dysfunctional Th2 response to an unknown inciting agent in the vascular wall, and that a multiplex ELISA or similar technology based a limited combination of KLS/KD pathogenesis-related cytokines (IL-6, IL-13, sTNFRII) and endothelial/smooth muscle chemokines (CCL1, CCL2, CxCL11) may provide an objective tool for diagnosing KLS and Kawasaki Disease. Because KD and HIV KLS are the only known "Th2" vasculitidies that spare the lungs (unique clinical presentation) and include plasma cell infiltration of the vascular wall as a prominent histopathologic feature (unique pathophysiology), a diagnostic test based on combinations of the above analytes will be highly specific and therefore clinically useful.

IPC Classes  ?

  • A61K 38/20 - Interleukins
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

79.

COMPOSITIONS AND SYSTEMS FOR CONFERRING DISEASE RESISTANCE IN PLANTS AND METHODS OF USE THEREOF

      
Application Number US2013057979
Publication Number 2014/042923
Status In Force
Filing Date 2013-09-04
Publication Date 2014-03-20
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Innes, Roger
  • Kim, Sang Hee
  • Qi, Dong

Abstract

Compositions, systems and methods are provided for conferring disease resistance to plant pathogens that use proteases to target plant substrate proteins inside plant cells. Briefly, the compositions, systems and methods are based upon plant substrate proteins that are targeted by pathogen-specific proteases and that activate nucleotide binding site-leucine rich repeat (NB-LRR) disease resistance proteins when cleaved by the protease. These substrate proteins are modified such that the endogenous protease recognition sequence is replaced by a protease recognition sequence specific to a different pathogen protease (i.e., a heterologous protease recognition sequence). The modified plant substrate protein therefore can be used in connection with its corresponding NB-LRR protein to activate resistance in response to cleavage by the heterologous pathogen-specific protease. When activated by the plant pathogen-specific protease, the pair initiates host defense responses thereto, including programmed cell death.

IPC Classes  ?

  • C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
  • C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
  • A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

80.

Secure and scalable mapping of human sequencing reads on hybrid clouds

      
Application Number 14116343
Grant Number 09276911
Status In Force
Filing Date 2012-05-14
First Publication Date 2014-03-13
Grant Date 2016-03-01
Owner Indiana University Research & Technology Corporation (USA)
Inventor
  • Wang, Xiaofeng
  • Tang, Haixu
  • Chen, Yangyi
  • Peng, Bo

Abstract

System and methods are provided for performing privacy-preserving, high-performance, and scalable DNA read mapping on hybrid clouds including a public cloud and a private cloud. The systems and methods offer strong privacy protection and have the capacity to process millions of reads and allocate most of the workload to the public cloud at a small overall cost. The systems and methods perform seeding on the public cloud using keyed hash values of individual sequencing reads' seeds and then extend matched seeds on the private cloud. The systems and methods are designed to move the workload of read mapping from the extension stage to the seeding stage, thereby ensuring that the dominant portion of the overhead is shouldered by the public cloud.

IPC Classes  ?

  • H04L 29/06 - Communication control; Communication processing characterised by a protocol
  • G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
  • G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
  • H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
  • H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system

81.

COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY

      
Application Number US2013050361
Publication Number 2014/012050
Status In Force
Filing Date 2013-07-12
Publication Date 2014-01-16
Owner
  • INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE UNIVERSITY OF MASSACHUSETTS (USA)
Inventor
  • Androphy, Elliot J.
  • Cherry, Jonathon J.
  • Cuny, Gregory D.
  • Glicksman, Marcie A.

Abstract

Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.

IPC Classes  ?

  • C07D 261/06 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/42 - Oxazoles
  • A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

82.

Epitope fluctuation and immunogenicity

      
Application Number 14000788
Grant Number 11468967
Status In Force
Filing Date 2012-03-05
First Publication Date 2013-12-12
Grant Date 2022-10-11
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP. (USA)
Inventor Ortoleva, Peter J.

Abstract

Systems and methods for computer-aided vaccine design may comprise performing one or more molecular dynamics simulations of a protein assembly having at least one epitope, determining a fluctuation measurement for the at least one epitope using the one or more molecular dynamics simulations, and predicting the immunogenicity of the protein assembly in response to the fluctuation measurement are disclosed.

IPC Classes  ?

  • G16B 5/30 - Dynamic-time models
  • G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
  • G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
  • G16B 15/20 - Protein or domain folding

83.

METHODS FOR GENERATING THE INNER EAR AND OTHER CRANIAL PLACODE-DERIVED TISSUES USING PLURIPOTENT STEM CELLS

      
Application Number US2013039686
Publication Number 2013/166488
Status In Force
Filing Date 2013-05-06
Publication Date 2013-11-07
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Hashino, Eri
  • Oxford, Gerry
  • Koehler, Karl, R.

Abstract

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

IPC Classes  ?

  • C12N 5/0793 - Neurons
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

84.

VIBRATOR FOR TOOTH MOVEMENT MODULATION

      
Application Number US2013028864
Publication Number 2013/142032
Status In Force
Filing Date 2013-03-04
Publication Date 2013-09-26
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Chen, Jie
  • Xia, Zeyang

Abstract

A handheld orthodontic tool includes a housing, electric motor, and a probe configured to engage a tooth. An operator applies manual pressure to the tooth with the probe, and the electric motor activates to vibrate the tooth through the probe. The orthodontic tool enables accelerating individual tooth or a group of teeth during orthodontic treatment to reach differential tooth movement speed, which will shorten the treatment time and reduce side effects including root resorption and anchorage loss.

IPC Classes  ?

  • A61C 7/00 - Orthodontics, i.e. obtaining or maintaining the desired position of teeth, e.g. by straightening, evening, regulating, separating, or by correcting malocclusions
  • A61C 7/10 - Devices having means to apply outwardly directed force, e.g. expanders
  • A61C 19/06 - Implements for therapeutic treatment

85.

CONDUIT IDENTIFICATION SYSTEM

      
Application Number US2013031645
Publication Number 2013/138649
Status In Force
Filing Date 2013-03-14
Publication Date 2013-09-19
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Campbell, Joseph
  • Brown, Wayman
  • Bang, Kyung-Hoon
  • Bonte, Rory
  • Finnell, John
  • Aldawsari, Mohammed

Abstract

An identifier for a conduit includes a substrate having a pair of apertures. The substrate further contains a frangible portion encompassing one of the apertures and having a shape that corresponds to an opening left in the substrate after removal of the frangible portion. The identifier enables the shape of the frangible portion to be correlated with the shape of the opening left in the substrate after the frangible portion is separated from the substrate.

IPC Classes  ?

  • H02G 1/08 - Methods or apparatus specially adapted for installing, maintaining, repairing, or dismantling electric cables or lines for laying cables, e.g. laying apparatus on vehicle through tubing or conduit, e.g. rod or draw wire for pushing or pulling

86.

A BIOMARKER FOR DETERMINING MITOCHONDRIAL DAMAGE IN FRIEDREICH'S ATAXIA

      
Application Number US2013028609
Publication Number 2013/130964
Status In Force
Filing Date 2013-03-01
Publication Date 2013-09-06
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Payne, Ronald Mark
  • Wagner, Gregory R.
  • Babbey, Clifford M.
  • Pride, P. Melanie

Abstract

Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mitochondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

87.

METHODS, SYSTEMS AND APPARATUSES FOR NIGHT AND DAY CORRECTIVE OPHTHALMIC PRESCRIPTION

      
Application Number US2013026868
Publication Number 2013/126410
Status In Force
Filing Date 2013-02-20
Publication Date 2013-08-29
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Thibos, Larry N.

Abstract

One exemplary embodiment is a method for determining an ophthalmic prescription. An examination room is lighted to simulate daytime viewing and a conventional eye chart is used as a visual stimulus. A first corrective spherical lens power is determined by varying spherical lens power and identifying when perceived vision is best. The examination room is kept dark to simulate nighttime viewing conditions. The visual stimulus utilized is a white point source on a dark background, or a self illuminated symbol on a dark background. A second corrective spherical lens powered is determined by varying spherical lens power and identifying when perceived vision is best. An ophthalmic prescription such as one or more lenses, one or more surgical corrections or a combinations thereof is provided including a first corrective component including the first preferred spherical lens power, and a second corrective component including the second preferred spherical lens power.

IPC Classes  ?

  • A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
  • G02C 7/02 - LensesLens systems

88.

METHOD AND APPARATUS THAT AUTOMATES TUBE CURRENT AND VOLTAGE SELECTION FOR CT SCANS

      
Application Number US2013020250
Publication Number 2013/103790
Status In Force
Filing Date 2013-01-04
Publication Date 2013-07-11
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Karmazyn, Boaz
  • Liang, Yun

Abstract

A CT scanner and method of operating the CT scanner enables customized automated selection of tube current and peak tube voltage for a CT scan. The CT scanner receives data, each datum of which corresponds to a reference image quality (noise level at a certain tube voltage) for patient water equivalent diameter (WED) body size. The CT scanner then stores the noise level and patient WED, and a processor in the CT scanner generates a curve corresponding to acceptable noise levels as a function of water equivalent diameter. The CT scanner stores the curve in a memory associated with the scanner and the CT scanner is subsequently operated with reference to the curve stored in the memory. The tube voltage that can generate the reference CT scan quality (signal-tonoise ratio) with the lowest radiation dose to the patient is selected.

IPC Classes  ?

89.

COMPOSITIONS FOR AND METHODS OF MODULATING COMPLICATIONS, RISKS AND ISSUES WITH XENOTRANSPLANTATION

      
Application Number US2012061637
Publication Number 2013/063076
Status In Force
Filing Date 2012-10-24
Publication Date 2013-05-02
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Tector, Alfred, Joseph Iii
  • Paris, Leela, L.

Abstract

Compositions are provided that include transgenic, non-human mammals, as well as organs, tissue and cells derived therefrom that express at least one heterologous immune- inhibitory molecule such as signal-regulatory protein alpha. Methods of using such transgenic, non-human mammals, organs, tissue and cells derived therefrom are provided for modulating the complications, issues and risks associated with xenotransplantation.

IPC Classes  ?

  • A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

90.

GIGAXONIN FUSION PROTEIN AND METHODS FOR TREATING GIANT AXONAL NEUROPATHY

      
Application Number US2012061979
Publication Number 2013/063309
Status In Force
Filing Date 2012-10-25
Publication Date 2013-05-02
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Payne, R. Mark
  • Babbey, Clifford M.
  • Martin, Kyle B.
  • Beard, Samuel M.

Abstract

The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.

IPC Classes  ?

  • C07K 19/00 - Hybrid peptides
  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • A61P 25/00 - Drugs for disorders of the nervous system

91.

Rho kinase inhibitors for treatment of mastocytosis and acute myeloid leukemia

      
Application Number 13586233
Grant Number 08518906
Status In Force
Filing Date 2012-08-15
First Publication Date 2013-02-21
Grant Date 2013-08-27
Owner Indiana University Research & Technology Corporation (USA)
Inventor Kapur, Reuben

Abstract

The disclosure is directed to methods of treating hematologic malignancies. More particularly, the disclosure is directed to methods of treating hematologic malignancies using Rho kinase (ROCK) inhibitors and myosin light chain-specific inhibitory RNA molecules. The disclosure is further directed to methods of identifying drug candidates for inhibiting ROCK in hematologic malignancies.

IPC Classes  ?

  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

92.

BIODEGREDATION SUPPRESSION SOLUTION FOR FORENSIC SAMPLES

      
Application Number US2012026286
Publication Number 2012/116158
Status In Force
Filing Date 2012-02-23
Publication Date 2012-08-30
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Goodpaster, John

Abstract

A biodegradation suppression system may include an anti-microbial agent, wherein the anti-microbial agent is effective to suppress biodegradation of ignitable liquid residues within a forensic sample. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of ignitable liquid residues within a forensic sample for a period of time. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of gasoline, wherein the solution is effective to allow for identification of at least one component of gasoline within the forensic sample.

IPC Classes  ?

  • A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
  • A01N 59/08 - Alkali metal chloridesAlkaline earth metal chlorides
  • A01N 29/08 - Halogen directly attached to a polycyclic ring system

93.

MATERIALS AND METHODS FOR IDENTIFYING PATIENTS SUSCEPTIBLE TO DEVELOPING TAXANE INDUCED NEUROPTHY

      
Application Number US2012023032
Publication Number 2012/103522
Status In Force
Filing Date 2012-01-27
Publication Date 2012-08-02
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Radovich, Milan
  • Schneider, Bryan, P.

Abstract

A randomized phase III study with a planned accmal (n=4950); GWAS performed ors 2204 patients to compare genotypes with efficacy and toxicities. The phenotype for this study is time to first grade 2-4 neuropathy. GVVAS is conducted using the Xnfmium HumanOmnil platform from Illumma which assessed 1.2 million SNPs per patient. Comparisons are made using Cox regression analysis with correction for multiple comparisons (Bonferroni) and established clinical trial co-variates (race, age, tumor size, LN status). Toxicity data indicates that 576 patients experienced grade 2-4 neuropathy and 1633 did not. Clinical predictors for neuropathy include age (12.9% increase with each decade; p=0.004) and African American race (HR=2.1; p=4.5 x 10-11). Six SNPs with MAF>5% demonstrate associations with neuropathy (ρ<5χ 10-7). These SNPs reside in two genes: RWDD3 and TECTA. A missense SNP in RWDD3 demonstrates % neuropathy at 15 months follow-up: 27% for homozygous wild-type, 40% for heterozygotes, and 60% for homozygous variant (allele dose-effect: HR=1.5; p=8.5 χ 10-8). Multiple other SNPs with MAF<5% were also associated with neuropathy (p<5x 10-7).

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof

94.

MULTI-TERMINAL NANOELECTRODE ARRAY

      
Application Number US2011055103
Publication Number 2012/048109
Status In Force
Filing Date 2011-10-06
Publication Date 2012-04-12
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Akingba, A. George
  • Chen, Peng-Sheng
  • Mahmood, Aamer

Abstract

An electrode for monitoring nerve activity has been developed. The electrode includes an array of electrically conductive projections extending from a surface of an electrical contact that enable the electrical contact to be connected directly to the nerve.

IPC Classes  ?

  • A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
  • A61H 39/00 - Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture

95.

LONG TERM VAGAL NERVE STIMULATION FOR THERAPEUTIC AND DIAGNOSTIC TREATMENT

      
Application Number US2011051924
Publication Number 2012/044472
Status In Force
Filing Date 2011-09-16
Publication Date 2012-04-05
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Chen, Peng-Sheng
  • Lin, Shien-Fong
  • Chen, Lan, S.

Abstract

A method of nerve stimulation produces therapeutic effects in an organ not directly innervated by the electrically stimulated nerve. The method includes identifying an electrical stimulation reaction threshold of at least one organ directly innervated by a parasympathetic nerve of a subject, identifying a reaction threshold of at least one tissue that is not directly innervated by the parasympathetic nerve of the subject after the parasympathetic nerve is electrically stimulated, and electrically stimulating the parasympathetic nerve with an electrical stimulation signal that is below the identified reaction threshold for the at least one directly innervated organ, but above a reaction threshold for the at least one tissue or organ that is not directly innervated by the parasympathetic nerve of the subject.

IPC Classes  ?

  • A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
  • A61N 1/362 - Heart stimulators

96.

LAYER-BY-LAYER NANOASSEMBLED NANOPARTICLES BASED THIN FILMS FOR SOLAR CELL AND OTHER APPLICATIONS

      
Application Number US2011045632
Publication Number 2012/015989
Status In Force
Filing Date 2011-07-27
Publication Date 2012-02-02
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Agarwal, Mangilal
  • Varahramyan, Khodadad
  • Shrestha, Sudhir

Abstract

A solar cell. The solar cell includes a substrate, a first layer comprising a first copper-based material deposited upon the substrate, the first copper-based material electrically attracted to the substrate or to a first optional deposit layer deposited between the substrate and the first layer, and a second layer comprising a second copper-based material deposited upon the first layer or an second optional deposit layer deposited between the first layer and the second layer, the second copper-based material electrically attracted to the first layer or to the second optional deposit layer, wherein the first copper-based material and the second copper-based material are selected from the group consisting of copper indium gallium (di)selenide (CIGS), copper indium selenium (CIS), and cadmium sulfate (CdS).

IPC Classes  ?

  • H01L 31/042 - PV modules or arrays of single PV cells
  • H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

97.

Material and methods for treating developmental disorders including comorbid and idiopathic autism

      
Application Number 13201014
Grant Number 09463172
Status In Force
Filing Date 2010-02-12
First Publication Date 2012-01-19
Grant Date 2016-10-11
Owner Indiana University Research & Technology Corporation (USA)
Inventor Erickson, Craig A.

Abstract

The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate. The acetylaminopropane sulfonate may have the following formula

IPC Classes  ?

  • A61K 31/16 - Amides, e.g. hydroxamic acids
  • A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K 31/4035 - Isoindoles, e.g. phthalimide

98.

Materials and methods to enhance hematopoietic stem cells engraftment procedures

      
Application Number 13128074
Grant Number 09107909
Status In Force
Filing Date 2009-11-06
First Publication Date 2012-01-05
Grant Date 2015-08-18
Owner Indiana University Research & Technology Corp. (USA)
Inventor
  • Pelus, Louis M.
  • Hoggatt, Jonathan
  • Singh, Pratibha

Abstract

2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

IPC Classes  ?

  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
  • C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
  • C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • C12N 5/0789 - Stem cellsMultipotent progenitor cells
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • A61K 35/14 - BloodArtificial blood
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61K 38/19 - CytokinesLymphokinesInterferons
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 5/16 - Animal cells
  • C12N 15/86 - Viral vectors
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

99.

System and method for detecting cardiac arrhythmias from heart nerve activity

      
Application Number 13127617
Grant Number 09375161
Status In Force
Filing Date 2009-10-28
First Publication Date 2011-09-08
Grant Date 2016-06-28
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor
  • Chen, Peng-Sheng
  • Lin, Shien-Fong

Abstract

A method has been developed that detects cardiac arrhythmia from intrinsic cardiac nerve signals obtained from a heart in a patient. The method includes sampling intrinsic cardiac nerve activity at a high sample rate, filtering the sampled signal with a high pass filter, comparing the filtered signal to a predetermined threshold, and initiating a therapeutic action in response to the filtered signal exceeding the predetermined threshold. The intrinsic cardiac nerve activity may be received through an electrode implanted on the heart or from an electrode inserted into the venous structure of the heart.

IPC Classes  ?

  • A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
  • A61B 5/04 - Measuring bioelectric signals of the body or parts thereof
  • A61B 5/00 - Measuring for diagnostic purposes Identification of persons
  • A61N 1/362 - Heart stimulators
  • A61N 1/39 - Heart defibrillators

100.

CENTRAL WIND TURBINE POWER GENERATION

      
Application Number US2010061972
Publication Number 2011/079246
Status In Force
Filing Date 2010-12-23
Publication Date 2011-06-30
Owner INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (USA)
Inventor Izadian, Afshin

Abstract

A wind power conversion apparatus for efficiently generating electric power is disclosed. The apparatus includes at least one blade, the at least one blade being configured to rotate when exposed to wind, a fluid pump mechanically coupled to the at least one blade and configured to pressurize fluid from a low pressure fluid to a high pressure fluid, a fluid motor fluidly coupled to the fluid pump and configured to rotate an output shaft in response to the high pressure fluid and thereby providing the low pressure fluid, and an electric generator mechanically coupled to the fluid motor and configured to generate electric power in response to the rotation of the output shaft of the fluid motor.

IPC Classes  ?

  • F03D 11/00 - Details, component parts, or accessories not provided for in, or of interest apart from, the other groups of this subclass
  • F03D 11/02 - Transmission of power, e.g. using hollow exhausting blades
  • F03D 1/00 - Wind motors with rotation axis substantially parallel to the air flow entering the rotor
  1     2        Next Page